Signals
8AL amyloidosis therapy reshapes around daratumumab and emerging amyloid-targeted programs
Daratumumab plus bortezomib first-line, isatuximab follow-on programs, and emerging anti-amyloid antibody therapy are restructuring AL amyloidosis management.
Hypertrophic cardiomyopathy myosin modulator class matures
Mavacamten commercial maturity, aficamten approval and pivotal data, and emerging follow-on cardiac myosin modulator programs are restructuring obstructive HCM management.
Lipid management therapy widens past statins and PCSK9 monoclonals
Inclisiran maturity, bempedoic acid, lepodisiran and emerging oral PCSK9 programs, and ANGPTL3-targeted therapy are restructuring lipid management.
Heart failure with reduced ejection fraction therapy moves beyond four-pillar standard
Vericiguat addition, mechanism-targeted programs, and emerging genetically-defined HFrEF approaches are reshaping the post-four-pillar landscape.
Chronic kidney disease therapy options widen in non-diabetic populations
Finerenone in non-diabetic CKD, SGLT2 expansion past diabetes, and novel mechanism programs are restructuring CKD management beyond the diabetic kidney disease frame.
Type 1 diabetes therapy reshapes around disease modification and automation
Teplizumab disease modification, automated insulin delivery system maturity, and emerging beta-cell replacement programs are restructuring T1D management.
MASH therapy class establishes after resmetirom approval
Resmetirom commercial uptake plus follow-on FGF21 analogues, GLP-1 plus glucagon, and PPAR-pan agonists are establishing a real metabolic-dysfunction-associated steatohepatitis prescribing class.
Apolipoprotein C3-targeted therapy expands lipid management
ApoC3-targeted programs are widening the triglyceride-lowering toolset and entering routine lipid practice.
Snapshots
2ATTR cardiomyopathy treatment landscape, 2026 mid-year reference
Reference layout of the ATTR cardiomyopathy treatment landscape as of mid-2026: TTR stabilisers, TTR silencers, the diagnostic-pathway infrastructure, and the live commercial questions including diagnostic-pathway expansion and combination therapy.
Obesity drug pipeline, 2026 mid-year reference
Reference layout of the obesity drug pipeline as of mid-2026: approved mechanisms, late-stage assets, the dual and triple agonist class, and the live commercial questions including manufacturing capacity, cardiovascular outcomes, and the indication-by-indication coverage frame.